Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) have earned an average recommendation of “Moderate Buy” from the five brokerages that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $15.50.

VTYX has been the subject of several analyst reports. Oppenheimer raised their price target on shares of Ventyx Biosciences from $9.00 to $14.00 and gave the company an “outperform” rating in a research note on Monday, October 27th. HC Wainwright raised Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 target price for the company in a research report on Wednesday, November 5th. Wells Fargo & Company lifted their target price on Ventyx Biosciences from $11.00 to $14.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ventyx Biosciences in a research note on Wednesday, October 8th. Finally, Canaccord Genuity Group raised their price objective on Ventyx Biosciences from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, November 7th.

Insider Buying and Selling

In related news, insider John Nuss sold 12,675 shares of the business’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total value of $97,851.00. Following the transaction, the insider owned 489,481 shares in the company, valued at $3,778,793.32. The trade was a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Raju Mohan sold 47,345 shares of the stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $365,503.40. Following the sale, the chief executive officer owned 2,372,863 shares of the company’s stock, valued at approximately $18,318,502.36. The trade was a 1.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 14.49% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in VTYX. Affinity Asset Advisors LLC bought a new stake in Ventyx Biosciences in the second quarter worth approximately $9,707,000. Marshall Wace LLP bought a new stake in shares of Ventyx Biosciences in the 2nd quarter valued at $5,129,000. Redmile Group LLC lifted its position in shares of Ventyx Biosciences by 1,164.1% during the 1st quarter. Redmile Group LLC now owns 1,569,793 shares of the company’s stock valued at $1,805,000 after acquiring an additional 1,445,615 shares during the period. Baker BROS. Advisors LP bought a new position in Ventyx Biosciences during the third quarter worth $3,182,000. Finally, AQR Capital Management LLC grew its holdings in Ventyx Biosciences by 925.6% in the first quarter. AQR Capital Management LLC now owns 880,222 shares of the company’s stock worth $1,012,000 after purchasing an additional 794,401 shares during the period. 97.88% of the stock is owned by institutional investors and hedge funds.

Ventyx Biosciences Trading Up 0.9%

Shares of VTYX stock opened at $9.26 on Friday. The firm has a market capitalization of $660.79 million, a price-to-earnings ratio of -6.17 and a beta of 1.22. The business’s 50-day moving average price is $8.44 and its 200-day moving average price is $4.73. Ventyx Biosciences has a 12 month low of $0.78 and a 12 month high of $10.55.

Ventyx Biosciences (NASDAQ:VTYX) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.13. On average, sell-side analysts predict that Ventyx Biosciences will post -2.09 earnings per share for the current fiscal year.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.